HD-OPM Archive
Topics › Infections & vaccines

COVID-OUT: early metformin cut long Covid risk by 42% in a large randomized trial

Louis Nervegna · Aug 22, 2024 · ♥ 13 reactions · 4 comments · original Facebook post
Infections & vaccinesInsulin resistance & diabetes
AI summary & key facts

The COVID-OUT phase 3 trial (>1000 mostly non-diabetic outpatients) found metformin lowered long Covid incidence by 42% relative to placebo, and by 63% when started within 4 days of symptoms. Ivermectin and fluvoxamine did not prevent long Covid.

The COVID-OUT trial, a large multi-center randomized controlled Phase 3 trial in the USA, demonstrated that metformin dramatically reduces the risk of Long Covid when used as a Covid treatment in an outpatient setting.

The trial included over 1000 people. Median age was 45, with about half male vs female. Metformin reduced the chances of getting Long Covid by 42% relative to placebo (p=0.009). Even better, when the metformin was started very early (<4 days of symptom onset), the risk was reduced by 63%. Note that the trial participants were mostly normal healthy people without diabetes. This was not a diabetes trial.

Treatment protocol: Metformin immediate release formulation: 500mg in AM on Day 1; 500mg in AM and PM on Day 2 through Day 5; 500mg in AM and 1,000mg in PM on Day 6 through Day 14.

Ivermectin and fluvoxamine both failed to prevent Long Covid in this trial.

“Interpretations: A 42% relative decrease and 4.3% absolute decrease in the Long COVID incidence occurred in participants who received early outpatient COVID-19 treatment with metformin compared to exact-matching placebo.”

PaperThe Lancet articlethelancet.com

#metforminHD #covidHD #longcovidHD #metformincovidHD #covidoutHD #longcovidHD #ivermectinHD #fluvoxamineHD

Research cited

← newer: Metformin reduced muscle atrophy and fibrosis during bed resolder: Metformin prevented periodontal disease in non-diabetics in →